Human Resources
Microsoft trial of a 4-day workweek shows productivity boost of 40%
An experiment that involved reducing the workweek by one day led to a 40% boost in productivity in a Microsoft subsidiary in Japan, the technology giant announced last week.
The trial was part of Microsoft’s “Work-Life Choice Challenge,” a summer project that examined work-life balance and aimed to help boost creativity and productivity by giving employees more flexible working hours.
Microsoft Japan closed its offices every Friday in August and found that labor productivity increased by 39.9% compared with August 2018, the company said. Full-time employees were given paid leave during the closures.
The company said it also reduced the time spent in meetings by implementing a 30-minute limit and encouraging remote communication.
Studies have found there’s demand for a shorter workweek. Last year, in a study of nearly 3,000 workers in eight countries by the Workforce Institute at Kronos and Future Workplace, most said their ideal workweek would be four days or less.
It’s not just the employees who benefited from Microsoft’s four-day-workweek experiment – Microsoft found that it helped preserve electricity and office resources as well. The number of pages printed decreased by 58.7%, while electricity consumption was down by 23.1% compared with August 2018, the company said.
You may also like Braving; The seven elements of trust
Register FREE to access Health Industry Hub’s e-news bulletin; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and key stakeholders.
News & Trends - MedTech & Diagnostics
AI-assisted colonoscopy boosts polyp and adenoma detection
MedTech & Diagnostics News: In a standard colonoscopy, as many as one-third of colorectal polyps and adenomas can go by […]
MoreNews & Trends - Pharmaceuticals
‘Every day of delay is costing Australian lives’, says Rare Cancers Australia CEO
Pharma News: Rare Cancers Australia (RCA) has voiced its disappointment alongside the pharmaceutical industry following the Pharmaceutical Benefits Advisory Committee’s […]
MoreNews & Trends - Pharmaceuticals
Government’s silence on Senate report leaves cancer patients in limbo
Pharma News: NeuroEndocrine Cancer Australia has urged the government to respond to the Senate report on equitable access to diagnosis […]
More